POLL: Looking Ahead to Winter Clinical Hawaii 2025
Are you attending Winter Clinical Hawaii? Answer our poll below to let us know.
Related Articles
Expert Insights Into L’OrĂ©al’s Voluntary Recall of Benzoyl Peroxide Products
Christopher Bunick, MD, PhD, explains what comes next for clinicians and patients.
L’OrĂ©al Issues Voluntary Recall of Benzoyl Peroxide Products Over Benzene Concerns
The recall includes L’OrĂ©al’s Effaclar Duo product. Stay tuned for more updates throughout the day.
Dermatology Times and Multimedia Medical, LLC
Dermatology Times asked our readers to share what conferences they are looking forward to in the third quarter of 2024. Keep up with the latest…
Jeff Stark, MD: Discussing Bimzelx’s Efficacy and Future in Treating Inflammatory Skin Diseases
Stark highlighted Bimzelx’s role in treating psoriasis and HS, introduced the BE BOLD study for PsA, and looked to future innovation in inflammatory skin disease.
Breakthrough Therapies in Itch Management: Insights From Brian S. Kim, MD, FAAD
Brian S. Kim, MD, FAAD, shares itch research updates at the AAD Annual Meeting.
Peter Lio, MD: Minimizing Discomfort in Dermatologic Procedures
Lio shared insights on minimizing pain in dermatologic procedures, highlighting practical techniques from his AAD 2025 presentations.
Michael Gold, MD: Mastering Device Complications and the Importance of Preparedness in Dermatology
Gold emphasized the necessity of recognizing and managing complications in aesthetic dermatology to ensure patient safety and optimal outcomes.
Understanding the Controversies in Lasers and Infantile Hemangiomas
Denise W. Metry, MD, FAAD, explored the controversies in using lasers in infantile hemangiomas at the AAD Annual Meeting.
Navigating the Corporate Structure to Get What You Need: Part 2
Keep these tips and pearls from dermatologic experts in mind for your next appointment.
Upadacitinib Shows Biomarker-Driven Efficacy in Nonsegmental Vitiligo
AbbVie’s phase 2 study demonstrates how upadacitinib reduces type 1 inflammation and boosts melanocyte biomarkers to drive vitiligo response.